Financial giants have made a conspicuous bullish move on Novavax. Our analysis of options history for Novavax NVAX revealed 14 unusual trades.
Delving into the details, we found 78% of traders were bullish, while 14% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $136,310, and 10 were calls, valued at $811,199.
Projected Price Targets
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $5.0 to $25.0 for Novavax over the recent three months.
Analyzing Volume & Open Interest
In terms of liquidity and interest, the mean open interest for Novavax options trades today is 8411.33 with a total volume of 3,784.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Novavax's big money trades within a strike price range of $5.0 to $25.0 over the last 30 days.
Novavax Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NVAX | CALL | TRADE | BULLISH | 01/17/25 | $7.8 | $7.65 | $7.75 | $5.00 | $193.7K | 12.9K | 6 |
| NVAX | CALL | SWEEP | BULLISH | 01/17/25 | $7.7 | $7.35 | $7.71 | $5.00 | $193.3K | 12.9K | 1.0K |
| NVAX | CALL | TRADE | NEUTRAL | 01/17/25 | $7.8 | $7.65 | $7.73 | $5.00 | $115.9K | 12.9K | 307 |
| NVAX | CALL | TRADE | BULLISH | 01/17/25 | $7.7 | $7.35 | $7.65 | $5.00 | $76.5K | 12.9K | 573 |
| NVAX | CALL | TRADE | BULLISH | 01/16/26 | $5.45 | $5.2 | $5.45 | $10.00 | $52.8K | 4.3K | 0 |
About Novavax
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
Novavax's Current Market Status
- With a trading volume of 6,106,747, the price of NVAX is up by 0.5%, reaching $12.0.
- Current RSI values indicate that the stock is may be approaching oversold.
- Next earnings report is scheduled for 26 days from now.
Professional Analyst Ratings for Novavax
In the last month, 1 experts released ratings on this stock with an average target price of $18.0.
- Consistent in their evaluation, an analyst from B of A Securities keeps a Neutral rating on Novavax with a target price of $18.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Novavax with Benzinga Pro for real-time alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
